(Total Views: 312)
Posted On: 08/23/2022 2:34:30 PM
Post# of 1460
The below was copied from IHUB from falconer66a,
Fletch
falconer66a
Tuesday, August 23, 2022 2:26:52 PM
Re: None
Post# of 371432
Is Science Translational Medicine a respected journal, read by medical researchers?
Well, it's one of the several journals published by the American Association for the Advancement of Science (AAAS), the premier professional science organization in the US. Pretty much, if you aren't a AAAS member you aren't a practicing scientist in the US. There is not a medical researcher who wouldn't want his or her article published in that journal. In every case such a publication is a resume enhancer.
Here's what AAAS tells about the publication:
Quote:Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest research advances from biomedical, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. In addition to original research, Science Translational Medicine also publishes Reviews, Editorials, Focus articles, and Viewpoints.
https://www.science.org/content/page/stm-information-authors
Medical researchers reading the new article won't discount it at all. Researchers and managers in drug development programs (in pharmaceutical companies) will read and comprehend the article. Unlike some of the expected posters here, external (non-Anavex) medical researchers won't be picking it apart, claiming that it's all wrong. Just the opposite. The evidence for the Anavex drug (blarcamesine) mechanism of action (MOA) becomes ever more solid. Every interested party will have to take Anavex into account. Anavex science is valid; can't be dismissed or discarded. It is going to change things.
https://investorshub.advfn.com/boards/read_ms...=169767040
Fletch
falconer66a
Tuesday, August 23, 2022 2:26:52 PM
Re: None
Post# of 371432
Is Science Translational Medicine a respected journal, read by medical researchers?
Well, it's one of the several journals published by the American Association for the Advancement of Science (AAAS), the premier professional science organization in the US. Pretty much, if you aren't a AAAS member you aren't a practicing scientist in the US. There is not a medical researcher who wouldn't want his or her article published in that journal. In every case such a publication is a resume enhancer.
Here's what AAAS tells about the publication:
Quote:Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering and medicine. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest research advances from biomedical, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. In addition to original research, Science Translational Medicine also publishes Reviews, Editorials, Focus articles, and Viewpoints.
https://www.science.org/content/page/stm-information-authors
Medical researchers reading the new article won't discount it at all. Researchers and managers in drug development programs (in pharmaceutical companies) will read and comprehend the article. Unlike some of the expected posters here, external (non-Anavex) medical researchers won't be picking it apart, claiming that it's all wrong. Just the opposite. The evidence for the Anavex drug (blarcamesine) mechanism of action (MOA) becomes ever more solid. Every interested party will have to take Anavex into account. Anavex science is valid; can't be dismissed or discarded. It is going to change things.
https://investorshub.advfn.com/boards/read_ms...=169767040
(1)
(0)Scroll down for more posts ▼
